Nachrichten zur Hims & Hers Health Aktie

…

Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase. See why I rate HIMS…

Apostrophe is folding back into Hims & Hers.…

We recently compiled a list of the 10 Best Skincare Stocks to Buy According to Hedge Funds. In this article,…

We recently compiled a list of the 10 Best Skincare Stocks to Buy According to Hedge Funds. In this article, we…

Insiders have been trading these 5 stocks: (($DUK)), (($BKNG)), (($HAL)), (($HIMS)) and (($IIPR)). Here is a breakdown of their recent…

Hims & Hers Health would discontinue Apostrophe, its personalized acne treatments dermatology business, the company said on Friday.…

Hims & Hers to shut down dermatology business Apostrophe…

Hims & Hers Health would discontinue Apostrophe, its personalized acne treatments dermatology business, the company said on Friday. …

Apostrophe is being shut down to "simplify its (companys) dermatology products and operations into one seamless experience," Hims & Hers…

Apostrophe is being shut down to "simplify its (companys) dermatology products and operations into one seamless experience," Hims & Hers…

(Reuters) -Hims & Hers Health would discontinue Apostrophe, its personalized acne treatments dermatology business, the company said on Friday. Apostrophe…

Hims & Hers Health (NYSE:HIMS) shut down Apostrophe on Friday, the skincare business it acquired in 2019 for $190M. A…

Hims and Hers is shutting down Apostrophe, the skincare company it acquired in 2021, after a tumultuous month for the…

Hims & Hers is shutting down its dermatology business, Business Insider has learned…

Hims & Hers is shutting down Apostrophe, the skincare company it acquired in 2021, after a tumultuous month for the…

We recently compiled a list of the 10 Stocks Drop Double Digits as Investor Caution Lingers. In this article, we are…

We recently compiled a list of the 10 Stocks Drop Double Digits as Investor Caution Lingers. In this article, we…

…

Hims & Hers Healths revenue grew 69% YoY, boosting its outlook. See why HIMS stock’s growth potential and high implied…

New York (www.aktiencheck.de) - Hims & Hers-Aktienanalyse der Citigroup: 1. Überblick über die Situation Citigroup erwartet, dass die Aktien von Hims &…

Hims & Hers Health (NYSE: HIMS) has been a top healthcare stock to own over the past five years, soaring…

Michael Cherny, an analyst from Leerink Partners, reiterated the Hold rating on Hims & Hers Health (HIMS – Research Report).…

New insider activity at Hims & Hers Health ( ($HIMS) ) has taken place on March 7, 2025. Director Pendarvis…

The courts decision affects shares of Hims & Hers Health.…

The ruling on a drug similar to one Hims & Hers sold dims the hope that a judge could allow…

Hims and Hers at Morgan Stanley Conference: Strategic Growth Insights…

Frankfurt (www.aktiencheck.de) - Hims & Hers Health-Aktienanalyse von XTB: Die Experten von XTB nehmen die Aktie von Hims & Hers Health,…

Hims & Hers Health (NYSE: HIMS) stock took a tumble Thursday morning, falling 9.2% through 11:40 a.m. ET on some…

** Shares of telehealth firm Hims & Hers NYSE:HIMS fall 9% to $37.2 premarket ** A U.S. federal judge has…

Citi maintains Sell rating on Hims & Hers stock, $27 target…

Hims & Hers Health falls as judge rules in favor of FDA in tirzepatide case…